OBJECTIVE: Evaluation of the efficacy of green tea extract (GTE) in regulating chemokine production and chemokine receptor expression in human RA synovial fibroblasts and rat adjuvant-induced arthritis (AIA). METHODS: Fibroblasts isolated from human RA synovium were used in the study. Regulated upon activation normal T cell expressed and secreted (RANTES)/CCL5, monocyte chemoattractant protein (MCP)-1/CCL2, growth-regulated oncogene (GRO)alpha/CXCL1 and IL-8/CXCL8 production was measured by ELISA. Western blotting was used to study the phosphorylation of protein kinase C (PKC)delta and c-Jun N-terminal kinases (JNK). Chemokine and chemokine receptor expression was determined by quantitative RT-PCR. The benefit of GTE administration in rat AIA was determined. RESULTS: GTE (2.5-40 microg/ml) inhibited IL-1beta-induced MCP-1/CCL2 (10 ng/ml), RANTES/CCL5, GROalpha/CXCL1 and IL-8/CXCL8 production in human RA synovial fibroblasts (P < 0.05). However, GTE inhibited MCP-1/CCL2 and GROalpha/CXCL1 mRNA synthesis in RA synovial fibroblasts. Furthermore, GTE also inhibited IL-1beta-induced phosphorylation of PKCdelta, the signalling pathway mediating IL-1beta-induced chemokine production. Interestingly, GTE preincubation enhanced constitutive and IL-1beta-induced CCR1, CCR2b, CCR5, CXCR1 and CXCR2 receptor expression. GTE administration (200 mg/kg/day p.o.) modestly ameliorated rat AIA, which was accompanied by a decrease in MCP-1/CCL2 and GROalpha/CXCL1 levels and enhanced CCR-1, -2, -5 and CXCR1 receptor expression in the joints of GTE administered rats. CONCLUSIONS: Chemokine receptor overexpression with reduced chemokine production by GTE may be one potential mechanism to limit the overall inflammation and joint destruction in RA.
OBJECTIVE: Evaluation of the efficacy of green tea extract (GTE) in regulating chemokine production and chemokine receptor expression in human RA synovial fibroblasts and rat adjuvant-induced arthritis (AIA). METHODS: Fibroblasts isolated from human RA synovium were used in the study. Regulated upon activation normal T cell expressed and secreted (RANTES)/CCL5, monocyte chemoattractant protein (MCP)-1/CCL2, growth-regulated oncogene (GRO)alpha/CXCL1 and IL-8/CXCL8 production was measured by ELISA. Western blotting was used to study the phosphorylation of protein kinase C (PKC)delta and c-Jun N-terminal kinases (JNK). Chemokine and chemokine receptor expression was determined by quantitative RT-PCR. The benefit of GTE administration in rat AIA was determined. RESULTS:GTE (2.5-40 microg/ml) inhibited IL-1beta-induced MCP-1/CCL2 (10 ng/ml), RANTES/CCL5, GROalpha/CXCL1 and IL-8/CXCL8 production in human RA synovial fibroblasts (P < 0.05). However, GTE inhibited MCP-1/CCL2 and GROalpha/CXCL1 mRNA synthesis in RA synovial fibroblasts. Furthermore, GTE also inhibited IL-1beta-induced phosphorylation of PKCdelta, the signalling pathway mediating IL-1beta-induced chemokine production. Interestingly, GTE preincubation enhanced constitutive and IL-1beta-induced CCR1, CCR2b, CCR5, CXCR1 and CXCR2 receptor expression. GTE administration (200 mg/kg/day p.o.) modestly ameliorated rat AIA, which was accompanied by a decrease in MCP-1/CCL2 and GROalpha/CXCL1 levels and enhanced CCR-1, -2, -5 and CXCR1 receptor expression in the joints of GTE administered rats. CONCLUSIONS:Chemokine receptor overexpression with reduced chemokine production by GTE may be one potential mechanism to limit the overall inflammation and joint destruction in RA.
Authors: Rosario García-Vicuña; Maria Victoria Gómez-Gaviro; Maria Jesús Domínguez-Luis; Martina K Pec; Isidoro González-Alvaro; Jose María Alvaro-Gracia; Federico Díaz-González Journal: Arthritis Rheum Date: 2004-12
Authors: Michael V Volin; Phillip L Campbell; Matthew A Connors; Drew C Woodruff; Alisa E Koch Journal: Exp Mol Pathol Date: 2002-10 Impact factor: 3.362
Authors: Takeo Isozaki; Mohammad A Amin; Jeffrey H Ruth; Phillip L Campbell; Pei-Suen Tsou; Christine M Ha; W Alex Stinson; Steven E Domino; Alisa E Koch Journal: Arthritis Rheumatol Date: 2014-08 Impact factor: 10.995
Authors: Shivaprasad H Venkatesha; Brian Astry; Siddaraju M Nanjundaiah; Hua Yu; Kamal D Moudgil Journal: Bioorg Med Chem Date: 2012-07-07 Impact factor: 3.641
Authors: Siddaraju M Nanjundaiah; David Y-W Lee; Zhongze Ma; Harry H S Fong; Lixing Lao; Brian M Berman; Kamal D Moudgil Journal: Evid Based Complement Alternat Med Date: 2012-03-07 Impact factor: 2.629
Authors: Brian Astry; Shivaprasad H Venkatesha; Arian Laurence; Aaron Christensen-Quick; Alfredo Garzino-Demo; Matthew B Frieman; John J O'Shea; Kamal D Moudgil Journal: Clin Immunol Date: 2015-02-07 Impact factor: 3.969